Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms
Madhu Shree
Poddar
a,
Yu-De
Chu
bcd,
Chau-Ting
Yeh
bcd and
Cheng-Hsien
Liu
*aef
aInstitute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu, 30044, Taiwan, Republic of China. E-mail: liuch@pme.nthu.edu.tw
bLiver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China
cMolecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan, Republic of China
dInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China
eDepartment of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China
fCollege of Semiconductor Research, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China
First published on 31st October 2024
Abstract
Correction for ‘Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms’ by Madhu Shree Poddar et al., Lab Chip, 2024, 24, 3668–3678, https://doi.org/10.1039/D4LC00238E.
The authors regret that in the above-titled article, Fig. 5 was presented incorrectly. Specifically, the images representing “Sorafenib + PBS (Monocancer)” and “Sorafenib + CD105 (Monocancer)” were identical, which was an unintentional mistake. The correct version of Fig. 5 is as follows:
 | ||
| Fig. 1 Cell viability tests were conducted on liver cancer cells with and without treatment with recombinant CD105 in the presence of Sorafenib. (a and c) Representative images of co-culture cell viability using Live/Dead staining assay after (a) 24- and (c) 48-hour incubation, comparing cells in each chamber with and without treatment with recombinant CD105, and with and without Sorafenib. A comparative analysis of cell viability among chambers and culture durations is shown in (b and d). The scale bar is 100 μm. | ||
This was a graphical error confined to this figure and does not affect the data, results, or conclusions of the study in any way.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2024 |